Cipla Gets Exclusive Rights to Distribute Pfizer Brands in India

Cipla has entered into a partnership with Pfizer to exclusively market and distribute five established Pfizer brands in the country. The collaboration strengthens Cipla’s footprint across key acute therapy segments while expanding patient access to widely prescribed medicines through a robust domestic distribution network.

Under the agreement, Cipla will have sole marketing and sales rights in India for Pfizer’s cough syrups Corex DX and Corex LS, the non-steroidal anti-inflammatory drug Dolonex, the proton pump inhibitor Nexium, and the oral antibiotic Dalacin C. Pfizer will continue to manufacture, source and supply these products for the Indian market, ensuring continuity in quality and supply. Industry estimates value the combined size of these brands at around Rs 400–430 crore.

Also Read: Navigating the New Era of Nitrosamine Compliance

“This partnership reflects our continued focus on expanding the reach of our medicines for patients in India,” said Meenakshi Nevatia, Country President, Pfizer India. She added that Cipla’s extensive distribution network, combined with Pfizer’s legacy of quality and innovation, would help improve access to trusted therapies across the country.

The collaboration aligns with its strategy of strengthening the India portfolio through selective, value-accretive partnerships. Achin Gupta, Global Chief Operating Officer, Cipla, said the collaboration aligns with Cipla’s strategy of strengthening its portfolio through meaningful partnerships. “Our distribution capabilities will support wider reach for these established brands,” he said.

Cipla is set to add high-prescription, well-recognised brands without taking on manufacturing risk. The partnership is expected to deepen Cipla’s presence in respiratory, pain management, gastroenterology and anti-infective segments, while improving portfolio depth in acute therapies alongside its strong chronic franchise.